Aster Capital Management’s Royalty Pharma RPRX Stock Holding History

Aster Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$220K	Buy	+3,919	New	+$204K	0.05%	393
2026 Q1	–	Sell	-2,244	Closed	-$86.7K	–	1259
2025 Q4	$86.7K	Sell	2,244 -4,357	-66%	-$166K	0.04%	371
2025 Q3	$233K	Buy	+6,601	New	+$239K	0.12%	226
2025 Q2	–	Sell	-5,085	Closed	-$171K	–	1497
2025 Q1	$171K	Buy	5,085 +195	+4%	+$6.18K	0.03%	520
2024 Q4	$125K	Buy	4,890 +1,312	+37%	+$34.8K	0.05%	342
2024 Q3	$101K	Buy	+3,578	New	+$99.1K	0.02%	375

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aster Capital Management's RPRX Position: Q2 2026 in Review

Aster Capital Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 3,919 shares worth $220K. The stake represents 0.05% of the portfolio and ranks #393 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in RPRX as recently as Q4 2025.

Aster Capital Management first reported a position in RPRX in Q3 2024 and has held it in 6 quarters since. The position peaked at $233K in Q3 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Aster Capital Management held 3,919 shares of Royalty Pharma worth $220K as of Q2 2026.
Royalty Pharma was a new Aster Capital Management position in Q2 2026.
Royalty Pharma made up 0.05% of Aster Capital Management's portfolio in Q2 2026, its #393 holding.
Aster Capital Management first reported a position in Royalty Pharma in Q3 2024 and has held it in 6 quarters since.
Aster Capital Management's Royalty Pharma position peaked at $233K in Q3 2025.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.